[Federal Register: March 15, 2004 (Volume 69, Number 50)]
[Notices]
[Page 12179]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15mr04-107]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 5, 2004, Mallinckrodt
Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made
application by renewal to the Drug Enforcement Administration (DEA) for
registration as a bulk manufacturer of the basic classes of controlled
substances listed below.
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Difenoxin (9168)........................... I
Heroin (9200).............................. I
Morphine-N-oxide (9307).................... I
Nicomorphine (9312)........................ I
Normorphine (9313)......................... I
Norlevorphanol (9634)...................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Etorphine HCL (9059)....................... II
Dihydrocodeine (9120)...................... II
Hydromorphone (9150)....................... II
Oxycodone (9143)........................... II
Diphenoxylate (9170)....................... II
Benzoylecgonine (9180)..................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
Metopon (9260)............................. II
Dextropropoxyphene (9273).................. II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The firm plans to manufacture the listed controlled substances for
internal use and for sale to other companies.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substance may file comments or objections
to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: Federal Register Representative,
Office of Chief Counsel (CCD) and must be filed no later than May 14,
2004.
Dated: March 5, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 04-5773 Filed 3-12-04; 8:45 am]
BILLING CODE 4410-09-M